Durvalumab (Imfinzi) in combination with chemotherapy produced outcomes consistent with prior studies in patients with advanced pleural mesothelioma, demonstrating favorable overall survival (OS), progression-free survival (PFS), and objective…
Durvalumab Plus Chemo Yields Inconclusive Results in Advanced Pleural Mesothelioma
